ERBB2 and ovarian cancer: This agent is approved for patients with germline BRCA-mutated, HER2-negative breast cancer in the metastatic setting [13]; for advanced ovarian cancer as first-line maintenance therapy, with bevacizumab for HRD tumors, and without bevacizumab in the context of germline or somatic BRCA mutations [29,30]; as maintenance therapy for recurrent ovarian cancer after partial or complete response to platinum-based therapy regardless of HR or BRCA status [18,31]; and as maintenance therapy for metastatic pancreatic cancer with germline BRCA mutations [32].